================================================================================
COLLECTED CLINICAL TRIALS REPORT
================================================================================
Collection Date: 2025-07-18 15:23:32
Total Studies: 14
Filter Criteria: Studies with results posted from 2020 onwards, excluding Phase 1, with publications
--------------------------------------------------------------------------------

1. Apalutamide Plus Cetrelimab in Patients With Treatment-Emergent Small Cell Neuroendocrine Prostate Cancer
   NCT ID: NCT04926181
   Status: TERMINATED
   Phase: PHASE2
   Condition: Small Cell Neuroendocrine Carcinoma; Prostate Cancer; Small Cell Carcinoma
   Intervention: Apalutamide; Cetrelimab
   Sponsor: Rahul Aggarwal
   Start Date: 2022-03-16
   Completion Date: 2024-03-31
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04926181
   Summary: Despite the low androgen receptor (AR) transcriptional activity of treatment-emergent small cell neuroendocrine prostate cancer, there is persistent AR expression observed in the majority of treatment-emergent small-cell neuroendocrine prostate cancer (t-SCNC) biopsies. This indicates that epigeneti...
   Locations: University of California, San Francisco, San Francisco, United States
----------------------------------------

2. Cabozantinib and Nivolumab for Carcinoid Tumors
   NCT ID: NCT04197310
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor; Carcinoid Tumor of GI System; Neuroendocrine Tumors
   Intervention: Nivolumab; Cabozantinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2019-12-26
   Completion Date: 2024-01-31
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04197310
   Summary: This research study, is studying the combination of cabozantinib and nivolumab in treating advanced carcinoid tumors.

- Carcinoid tumor is another term used to refer to neuroendocrine tumors that arise in organs such as the gastrointestinal tract, lungs, or thymus.
   Locations: Boston Medical Center, Boston, United States; Dana Farber Cancer Institute, Boston, United States
----------------------------------------

3. AMT-PET in Monitoring Telotristat Etiprate Treatment in Participants With MetastaticNeuroendocrine Neoplasm
   NCT ID: NCT03453489
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Syndrome; Metastatic Nonfunctional Well Differentiated Neuroendocrine Neoplasm
   Intervention: Carbon C 11 Alpha-methyltryptophan; Laboratory Biomarker Analysis; Positron Emission Tomography; Telotristat Etiprate
   Sponsor: Barbara Ann Karmanos Cancer Institute
   Start Date: 2018-06-20
   Completion Date: 2020-10-15
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03453489
   Summary: This pilot trial studies how well telotristat etiprate works in treating participants with well differentiated neuroendocrine neoplasm that has spread to other places in the body and monitored by carbon C 11 alpha-methyltryptophan (AMT)-emission tomography (PET). Telotristat etiprate may stop the gr...
   Locations: Wayne State University/Karmanos Cancer Institute, Detroit, United States
----------------------------------------

4. Antiandrogen Therapy, Abiraterone Acetate, and Prednisone With or Without Neutron Radiation Therapy in Treating Patients With Prostate Cancer
   NCT ID: NCT03649841
   Status: TERMINATED
   Phase: PHASE2
   Condition: Castration-Sensitive Prostate Carcinoma; Metastatic Malignant Neoplasm in the Bone; Metastatic Prostate Carcinoma; Prostate Adenocarcinoma; Prostate Small Cell Neuroendocrine Carcinoma; Stage IV Prostate Cancer AJCC v8; Stage IVA Prostate Cancer AJCC v8; Stage IVB Prostate Cancer AJCC v8
   Intervention: Antiandrogen Therapy; Abiraterone Acetate; Prednisone; Radiation Therapy
   Sponsor: University of Washington
   Start Date: 2020-06-29
   Completion Date: 2023-02-01
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03649841
   Summary: This phase II trial studies how well antiandrogen therapy, abiraterone acetate, and prednisone with or without neutron radiation therapy work in treating patients with prostate cancer. Hormone therapy such as antiandrogen therapy may fight prostate cancer by blocking the production and interfering w...
   Locations: Fred Hutch/University of Washington Cancer Consortium, Seattle, United States
----------------------------------------

5. Phase II Study of Pembrolizumab and Lenvatinib in Advanced Well-differentiated Neuroendocrine Tumors
   NCT ID: NCT03290079
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Neuroendocrine Carcinoma; Neuroendocrine Cancer
   Intervention: Pembrolizumab; Lenvatinib
   Sponsor: H. Lee Moffitt Cancer Center and Research Institute
   Start Date: 2017-12-15
   Completion Date: 2024-05-13
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03290079
   Summary: The purpose of this study is to:

* Assess overall radiographic response rate (ORR)
* Assess progression-free survival (PFS)
* Test the safety and tolerability of Pembrolizumab in combination with lenvatinib
   Locations: H. Lee Moffitt Cancer Center and Research Institute, Tampa, United States
----------------------------------------

6. Study of Lanreotide in Patients With Metastatic Gastrointestinal Neuroendocrine Tumors Who Are Undergoing Liver-directed Radioembolization With Yttrium-90 Microspheres
   NCT ID: NCT02859064
   Status: TERMINATED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Gastrointestinal Neoplasms; Carcinoid Tumors
   Intervention: Lanreotide; Y-90 microspheres
   Sponsor: SCRI Development Innovations, LLC
   Start Date: 2017-07-28
   Completion Date: 2022-06-10
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02859064
   Summary: Neuroendocrine tumors (NETs) and cancers that originate from the gastrointestinal tract can be resistant to standard chemotherapy and often metastasize to the liver. Lanreotide (Somatuline® Depot) Injection and Yttrium-90 microspheres (SIR-Spheres®) each have FDA approval to treat patients with meta...
   Locations: Rocky Mountain Cancer Center, Denver, United States; Research Medical Center/HCA Midwest, Kansas City, United States; Tennessee Oncology PLLC, Nashville, United States
----------------------------------------

7. Nivolumab With Ipilimumab in Subjects With Neuroendocrine Tumors
   NCT ID: NCT03420521
   Status: TERMINATED
   Phase: PHASE2
   Condition: Neuroendocrine Tumors; Carcinoid Tumor
   Intervention: Nivolumab; Ipilimumab
   Sponsor: Sidney Kimmel Comprehensive Cancer Center at Johns Hopkins
   Start Date: 2018-03-09
   Completion Date: 2021-11-24
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT03420521
   Summary: This is a single arm open-label design study looking at Nivolumab plus Ipilimumab in patients with Advanced Neuroendocrine Tumors. Patients will be dosed Nivolumab 240mg IV over 60 minutes every 2 weeks (Q2W) and Ipilimumab 1mg/kg IV over 30 minutes every 6 weeks (Q6W). One cycle will include 3 dose...
   Locations: Johns Hopkins Medical Institution, Baltimore, United States
----------------------------------------

8. Carfilzomib for the Treatment of Patients With Advanced Neuroendocrine Cancers
   NCT ID: NCT02318784
   Status: COMPLETED
   Phase: PHASE2
   Condition: Neuroendocrine Cancer
   Intervention: Carfilzomib
   Sponsor: SCRI Development Innovations, LLC
   Start Date: 2015-07-15
   Completion Date: 2021-05-15
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02318784
   Summary: The purpose of this study is to determine if carfilzomib is safe and effective in the treatment of patients with advanced neuroendocrine tumors.
   Locations: Rocky Mountain Cancer Center, Denver, United States; Florida Cancer Specialists, Fort Myers, United States; Florida Hospital Cancer Institute, Orlando, United States
              ... and 7 more locations
----------------------------------------

9. Lurbinectedin Monotherapy in Participants With Advanced or Metastatic Solid Tumors
   NCT ID: NCT05126433
   Status: TERMINATED
   Phase: PHASE2
   Condition: Advanced Solid Tumor; Metastatic Solid Tumor; Urothelial Cancer; Poorly Differentiated Neuroendocrine Carcinomas; Homologous Recombination Deficient-Positive Malignancies Agnostic
   Intervention: Lurbinectedin
   Sponsor: Jazz Pharmaceuticals
   Start Date: 2022-03-03
   Completion Date: 2023-12-20
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT05126433
   Summary: This is an open-label, multicenter, phase 2 study of lurbinectedin monotherapy in participants with advanced (metastatic and/or unresectable) solid tumors.
   Locations: Stanford Cancer Center, Stanford, United States; Eastern Connecticut Hematology and Oncology, Norwich, United States; Florida Cancer Specialists, Fort Myers, United States
              ... and 14 more locations
----------------------------------------

10. Ziv-Aflibercept in Treating and Computed Tomography Perfusion Imaging in Predicting Response in Patients With Pancreatic Neuroendocrine Tumors That Are Metastatic or Cannot Be Removed by Surgery
   NCT ID: NCT02101918
   Status: COMPLETED
   Phase: PHASE2
   Condition: Multiple Endocrine Neoplasia Type 1; Pancreatic Neuroendocrine Carcinoma
   Intervention: Computed Tomography Perfusion Imaging; Laboratory Biomarker Analysis; Ziv-Aflibercept
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2014-06-18
   Completion Date: 2018-01-31
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02101918
   Summary: This phase II trial studies ziv-aflibercept in treating and perfusion computed tomography perfusion imaging in predicting response in patients with pancreatic neuroendocrine tumors that have spread to other parts of the body or cannot be removed by surgery. Ziv-aflibercept may stop the growth of tum...
   Locations: Moffitt Cancer Center-International Plaza, Tampa, United States; Moffitt Cancer Center, Tampa, United States; M D Anderson Cancer Center, Houston, United States
----------------------------------------

11. Cabozantinib in Advanced Pancreatic Neuroendocrine and Carcinoid Tumors
   NCT ID: NCT01466036
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor; Pancreatic Neuroendocrine Tumor
   Intervention: Cabozantinib
   Sponsor: Dana-Farber Cancer Institute
   Start Date: 2012-07
   Completion Date: 2023-12
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT01466036
   Summary: Cabozantinib works by blocking the growth of new blood vessels that feed a tumor. In addition to blocking the formation of new blood cells in tumors, cabozantinib also blocks pathways that may be responsible for allowing cancers cells to become resistant to other "anti-angiogenic" drugs. Cabozantini...
   Locations: Massachusetts General Hospital, Boston, United States; Dana-Farber Cancer Institute, Boston, United States
----------------------------------------

12. Nintedanib in Treating Patients With Locally Advanced or Metastatic Neuroendocrine Tumors
   NCT ID: NCT02399215
   Status: COMPLETED
   Phase: PHASE2
   Condition: Carcinoid Tumor; Metastatic Carcinoid Tumor; Neuroendocrine Neoplasm
   Intervention: Laboratory Biomarker Analysis; Nintedanib; Pharmacological Study; Quality-of-Life Assessment
   Sponsor: Roswell Park Cancer Institute
   Start Date: 2015-05-15
   Completion Date: 2022-08-31
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02399215
   Summary: This phase II trial studies how well nintedanib works in treating patients with neuroendocrine tumors that have spread from where they started to nearby tissue or lymph nodes (locally advanced) or have spread from the primary site (place where they started) to other places in the body (metastatic). ...
   Locations: Roswell Park Cancer Institute, Buffalo, United States; Ohio State University Comprehensive Cancer Center, Columbus, United States
----------------------------------------

13. A Home-Based Approach Study to Evaluate the Efficacy and Safety of Alectinib in Locally-Advanced or Metastatic ALK-Positive Solid Tumors
   NCT ID: NCT04644315
   Status: TERMINATED
   Phase: PHASE2
   Condition: Neoplasms; Colorectal Neoplasms; Melanoma; Pancreatic Neoplasms; Sarcoma; Ovarian Neoplasms; Brain Neoplasms; Thyroid Neoplasms; Neuroendocrine Tumors; Cholangiocarcinoma; Salivary Gland Neoplasms; Head and Neck Neoplasms; Thyroid Cancer, Papillary; Lymphoma, Large-Cell, Anaplastic; Neoplasms by Site; Respiratory Tract Neoplasms; Thoracic Neoplasms; Respiratory Tract Diseases; Carcinoma, Bronchogenic; Bronchial Neoplasms; Intestinal Neoplasms; Gastrointestinal Neoplasms; Digestive System Neoplasms; Digestive System Diseases; Gastrointestinal Diseases; Colonic Diseases; Intestinal Diseases; Central Nervous System
   Intervention: Alectinib
   Sponsor: Hoffmann-La Roche
   Start Date: 2021-05-24
   Completion Date: 2022-05-16
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT04644315
   Summary: This study will evaluate the efficacy and safety of alectinib in participants with Anaplastic Lymphoma Kinase (ALK)-positive locally advanced or metastatic solid tumors other than lung cancer.
   Locations: Science 37, Inc, Culver City, United States; Science 37-Basem; Dept 004- Basem, Culver City, United States; Science 37-Beg; Dept 001 Dr. M. Beg, Culver City, United States
              ... and 26 more locations
----------------------------------------

14. Sapanisertib in Treating Patients With Metastatic or Refractory Pancreatic Neuroendocrine Tumor That Cannot Be Removed by Surgery
   NCT ID: NCT02893930
   Status: COMPLETED
   Phase: PHASE2
   Condition: Pancreatic Neuroendocrine Tumor G1; Pancreatic Neuroendocrine Tumor G2; Refractory Pancreatic Neuroendocrine Carcinoma
   Intervention: Sapanisertib
   Sponsor: National Cancer Institute (NCI)
   Start Date: 2017-04-28
   Completion Date: 2022-12-21
   Has Posted Results: True
   Publications Count: 0
   Search Terms Matched: simple_net_search
   URL: https://clinicaltrials.gov/study/NCT02893930
   Summary: This phase II trial studies how well sapanisertib works in treating patients with pancreatic neuroendocrine tumor that has spread to other places in the body (metastatic), does not respond to treatment (refractory), or cannot be surgically removed. Drugs such as sapanisertib may stop the growth or s...
   Locations: Mayo Clinic Hospital in Arizona, Phoenix, United States; Mayo Clinic in Arizona, Scottsdale, United States; CHI Saint Vincent Cancer Center Hot Springs, Hot Springs, United States
              ... and 402 more locations
----------------------------------------

